var data={"title":"Infliximab (including biosimilars of infliximab): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Infliximab (including biosimilars of infliximab): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6369?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=infliximab-including-biosimilars-of-infliximab-drug-information\" class=\"drug drug_general\">see &quot;Infliximab (including biosimilars of infliximab): Drug information&quot;</a> and <a href=\"topic.htm?path=infliximab-including-biosimilars-of-infliximab-patient-drug-information\" class=\"drug drug_patient\">see &quot;Infliximab (including biosimilars of infliximab): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708921\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Serious infections:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Patients treated with infliximab are at an increased risk of developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants, such as methotrexate or corticosteroids.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Discontinue infliximab if a patient develops a serious infection or sepsis.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Reported infections include the following:</p>\n        <p style=\"text-indent:-2em;margin-left:6em;\">Active tuberculosis (TB), including reactivation of latent TB. Patients with TB have frequently presented with disseminated or extrapulmonary disease. Patients should be tested for latent TB before infliximab use and during therapy. Treatment for latent infection should be initiated prior to infliximab use.</p>\n        <p style=\"text-indent:-2em;margin-left:6em;\">Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Empiric antifungal therapy should be considered in patients at risk of invasive fungal infections who develop severe systemic illness.</p>\n        <p style=\"text-indent:-2em;margin-left:6em;\">Bacterial, viral, and other infections caused by opportunistic pathogens, including <i>Legionella</i> and <i>Listeria</i>.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">The risks and benefits of treatment with infliximab should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with infliximab, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Malignancy:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with tumor necrosis factor (TNF) blockers, including infliximab.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Postmarketing cases of hepatosplenic T-cell lymphoma, a rare type of T-cell lymphoma, have been reported in patients treated with TNF blockers, including infliximab. These cases have had a very aggressive disease course and have been fatal. Almost all patients had received treatment with azathioprine or 6-mercaptopurine concomitantly with a TNF-blocker at or prior to diagnosis. The majority of reported infliximab cases have occurred in patients with Crohn disease or ulcerative colitis, and most were in adolescent and young adult males.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182756\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Inflectra;</li>\n      <li>Remicade;</li>\n      <li>Renflexis</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182757\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Inflectra;</li>\n      <li>Remicade;</li>\n      <li>Remsima</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047891\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antirheumatic, Disease Modifying</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Gastrointestinal Agent, Miscellaneous</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Immunosuppressant Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Monoclonal Antibody</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Tumor Necrosis Factor (TNF) Blocking Agent</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047884\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=infliximab-including-biosimilars-of-infliximab-drug-information\" class=\"drug drug_general\">see &quot;Infliximab (including biosimilars of infliximab): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Premedication with antihistamines (H<sub>1</sub>-antagonist and/or H<sub>2</sub>-antagonist), acetaminophen and/or corticosteroids may be considered to prevent and/or manage infusion-related reactions: Renflexis (infliximab-abda) and Inflectra (infliximab-dyyb) are approved as biosimilar to Remicade. Approved uses for biosimilar agents may vary (consult product labeling).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Crohn disease:</b> Remicade/Inflectra/Renflexis: Children &ge;6 years and Adolescents: IV: Initial: 5 mg/kg/dose at 0, 2, and 6 weeks, followed by maintenance: 5 mg/kg/dose every 8 weeks thereafter. <b>Note: </b>If the response is incomplete, dose has been increased up to 10 mg/kg (Rufo 2012; Stephens 2003); in adult patients with Crohn disease, it has been observed that patients who do not respond by week 14 are unlikely to respond with continued dosing; consider therapy discontinuation in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Juvenile idiopathic arthritis; refractory to conventional disease-modifying drugs:</b> Limited data available: Children &ge;4 years and Adolescents: IV: Initial: 3 mg/kg at 0, 2, and 6 weeks; then 3 to 6 mg/kg/dose every 8 weeks thereafter, in combination with methotrexate during induction and maintenance (Ruperto 2010). Alternatively, some studies used 6 mg/kg/dose starting at week 14 of a methotrexate induction regimen (weeks 0 to 13); repeat dose (6 mg/kg/dose) at week 16 and 20, then every 8 weeks thereafter. <b>Note:</b> Trials performed with Remicade product (Ruperto 2007; Ruperto 2010; Visvanathan 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Kawasaki disease, refractory to IVIG: </b>Limited data available: Infants and Children: IV: 5 mg/kg/dose as a single infusion (AHA [McCrindle 2017]; Burns 2005; Burns 2008; Son 2011; Weiss 2004; Youn 2016)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Ulcerative colitis:</b> Remicade: Children &ge;6 years and Adolescents: IV: Initial: 5 mg/kg/dose at 0, 2, and 6 weeks, followed by maintenance: 5 mg/kg/dose every 8 weeks thereafter. <b>Note:</b> If the response is incomplete, dose has been increased up to 10 mg/kg (Rufo 2012; Stephens 2003)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Crohn disease:</b> IV: 5 mg/kg at 0, 2, and 6 weeks, followed by 5 mg/kg every 8 weeks thereafter; dose may be increased to 10 mg/kg in patients who respond but then lose their response. If no response by week 14, consider discontinuing therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Rheumatoid arthritis (in combination with methotrexate):</b> IV: Initial: 3 mg/kg at 0, 2, and 6 weeks, followed by 3 mg/kg every 8 weeks thereafter; doses have ranged from 3 to 10 mg/kg repeated at 4- to 8-week intervals</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Ankylosing spondylitis:</b> IV: 5 mg/kg at 0, 2, and 6 weeks, followed by 5 mg/kg every 6 weeks thereafter</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Plaque psoriasis: </b>IV: 5 mg/kg at 0, 2, and 6 weeks, followed by 5 mg/kg every 8 weeks thereafter</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Psoriatic arthritis (with or without methotrexate):</b> IV: 5 mg/kg at 0, 2, and 6 weeks, followed by 5 mg/kg every 8 weeks thereafter</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Ulcerative colitis:</b> IV: 5 mg/kg at 0, 2, and 6 weeks, followed by 5 mg/kg every 8 weeks thereafter</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Dosage adjustment with heart failure (HF):</b> Adults: Weigh risk versus benefits for individual patient:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Mild HF (NYHA Class I/II): </i>No dosage adjustment necessary; use with caution and monitor closely for worsening of HF</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Moderate to severe (NYHA Class III or IV):</i> &le;5 mg/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182738\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Inflectra: infliximab-dyyb 100 mg (1 ea) [contains polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Remicade: 100 mg (1 ea) [contains polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Renflexis: infliximab-abda 100 mg (1 ea) [contains polysorbate 80]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182723\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27749143\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span><p>(For additional information <a href=\"topic.htm?path=infliximab-including-biosimilars-of-infliximab-drug-information\" class=\"drug drug_general\">see &quot;Infliximab (including biosimilars of infliximab): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infliximab-abda (Renflexis), infliximab-dyyb (Inflectra), infliximab-qbtx (Ixifi), and Remsima [Canadian product] are approved as biosimilar to Remicade.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Remicade contains sucrose 500 mg per vial.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50858894\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Ixifi (infliximab-qbtx): FDA approved December 2017; anticipated availability is currently undetermined.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7874621\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Remicade: <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/103772s5377lbl.pdf#page=48&amp;token=w+qfyl11AzX2CakqwTlx0ziep+obGMs6Bk9ShPxDKLr+/pftg0T4o6ffHP4942rEtky0b8h78dAJluZ1uerKH2WQD+eb7UX3pdHk6y70R0/t4feAzTBW9N/w+Y6A+Owl&amp;TOPIC_ID=13381\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/103772s5377lbl.pdf#page=48</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Inflectra: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM497384.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/8bxp4YrxUVJFUAWh6274gi3LbMdiQvFNuvjB+hSaKSgw==&amp;TOPIC_ID=13381\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM497384.pdf</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renflexis (infliximab-abda): <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM497384.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/8bxp4YrxUVJFUAWh6274gi3LbMdiQvFNuvjB+hSaKSgw==&amp;TOPIC_ID=13381\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761054lbl.pdf#page=51</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047894\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Parenteral: The infusion should begin within 3 hours of preparation. Administer by IV infusion through an in-line, sterile, nonpyrogenic, low-protein-binding filter with pore size of &le;1.2 micrometers; do not infuse in the same IV line as other agents. Infuse over at least 2 hours; a rate titration schedule may be used to prevent acute infusion reactions. Temporarily discontinue or decrease infusion rate with infusion-related reactions. Antihistamines (H<sub>1</sub>-antagonist &plusmn; H<sub>2</sub>-antagonist), acetaminophen and/or corticosteroids may be used to manage reactions. Infusion may be reinitiated at a lower rate upon resolution of mild to moderate symptoms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adults: Guidelines for the treatment and prophylaxis of infusion reactions: Data limited to adult patients and dosages used in Crohn; prospective data for other populations (pediatrics, other indications/dosing) are not available. A protocol for the treatment of infusion reactions, as well as prophylactic therapy for repeat infusions, has been published (Mayer 2006).</p>\n    <p style=\"text-indent:0em;margin-left:2em;margin-top:2em;\">\n      <i>Treatment of infusion reactions:</i> Medications for the treatment of hypersensitivity reactions should be available for immediate use. For mild reactions, the rate of infusion should be decreased to 10 mL/hour. Initiate a NS infusion (500 to 1,000 mL/hour) and appropriate symptomatic treatment (eg, acetaminophen and diphenhydramine); monitor vital signs every 10 minutes until normal. After 20 minutes, the infliximab infusion may be increased at 15-minute intervals, as tolerated, to completion [initial increase to 20 mL/hour, then 40 mL/hour, then 80 mL/hour, etc (maximum of 125 mL/hour)]. For moderate reactions, the infusion should be stopped or slowed. Initiate a NS (500 to 1,000 mL/hour) and appropriate symptomatic treatment. Monitor vital signs every 5 minutes until normal. After 20 minutes, the infliximab infusion may be reinstituted at 10 mL/hour; then increased at 15-minute intervals, as tolerated, to completion [initial increase 20 mL/hour, then 40 mL/hour, then 80 mL/hour, etc (maximum of 125 mL/hour)]. For severe reactions, the infusion should be stopped with administration of appropriate symptomatic treatment (eg, hydrocortisone/methylprednisolone, diphenhydramine, and epinephrine) and frequent monitoring of vitals. Retreatment after a severe reaction should only be done if the benefits outweigh the risks and with appropriate prophylaxis. Delayed infusion reactions typically occur 1 to 7 days after an infusion. Treatment should consist of appropriate symptomatic treatment (eg, acetaminophen, antihistamine, and methylprednisolone).</p>\n    <p style=\"text-indent:0em;margin-left:2em;margin-top:2em;\">\n      <i>Prophylaxis of infusion reactions:</i> Premedication with acetaminophen and diphenhydramine 90 minutes prior to infusion may be considered in all patients with prior infusion reactions, and in patients with severe reactions corticosteroid administration is recommended. Steroid dosing may be oral (prednisone 50 mg orally every 12 hours for 3 doses prior to infusion) or intravenous (a single dose of hydrocortisone 100 mg or methylprednisolone 20 to 40 mg administered 20 minutes prior to the infusion). On initiation of the infusion, begin with a test dose at 10 mL/hour of infliximab for 15 minutes. Thereafter, the infusion may be increased at 15-minute intervals, as tolerated, to completion (initial increase 20 mL/hour, then 40 mL/hour, then 80 mL/hour, etc). A maximum rate of 125 mL/hour is recommended in patients who experienced prior mild-moderate reactions and 100 mL/hour is recommended in patients who experienced prior severe reactions. In patients with cutaneous flushing, aspirin may be considered (Becker 2004). For delayed infusion reactions, premedicate with acetaminophen and diphenhydramine 90 minutes prior to infusion. On initiation of the infusion, begin with a test dose at 10 mL/hour for 15 minutes. Thereafter, the infusion may be increased to infuse over 3 hours. Postinfusion therapy with acetaminophen for 3 days and an antihistamine for 7 days is recommended. <b>Note:</b> In a trial of pediatric patients, premedication with acetaminophen (20 mg/kg; maximum single dose: 1,000 mg) and cetirizine (0.3 mg/kg if &lt;5 years, 10 mg if &ge;5 years) did not significantly impact incidence of infusion-related reactions; patients should be monitored closely (Lahdenne 2010).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182751\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store intact vials at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); may be stored at room temperature (maximum of 30&deg;C [86&deg;F]) for up to 6 months (not to exceed the original expiration date); do not return to refrigerated storage. The manufacturer recommends that solutions diluted in NS for infusion should be used within 3 hours of preparation. However, a stability study of infliximab 0.4 mg/mL prepared in NS in polyvinyl chloride (PVC) bags found no loss of biological activity when stored refrigerated at 4&deg;C for up to 14 days (Ikeda 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047893\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of patients with moderately to severely active ulcerative colitis with inadequate response to conventional therapy (to reduce signs/symptoms and induce and maintain clinical remission, mucosal healing and eliminate corticosteroid use) (Remicade: FDA approved in children &ge;6 years and adults; Inflectra, Renflexis: FDA approved in adults); Crohn disease who have had inadequate responses to conventional therapy (to reduce signs/symptoms and induce and maintain clinical remission) (Remicade, Inflectra, Renflexis: FDA approved in children &ge;6 years and adults) or to reduce the number of draining enterocutaneous and rectovaginal fistulas and maintain fistula closure (Remicade, Inflectra, Renflexis: FDA approved in adults); reduction of signs and symptoms of ankylosing spondylitis (Remicade, Inflectra, Renflexis: FDA approved in adults); treatment of psoriatic arthritis (to reduce signs/symptoms of active arthritis and inhibit progression of structural damage and improve physical function) (Remicade, Inflectra, Renflexis: FDA approved in adults); treatment of chronic severe (extensive and/or disabling) plaque psoriasis who require systemic therapy and other systemic therapies are less appropriate (Remicade, Inflectra, Renflexis: FDA approved in adults); has also been used for management of Kawasaki disease refractory to intravenous immunoglobulin (IVIG)</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <b>Note: </b>Infectra (Infliximab-dyyb) and Renflexis (Infliximab-abda) are biosimilar agents; approved uses and ages may vary, see product labeling for additional information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182793\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">InFLIXimab may be confused with idaruCIZUmab, riTUXimab</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Remicade may be confused with Renacidin, Rituxan</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes that have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182789\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Flushing (children and adolescents with Crohn disease), hypertension</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Fatigue, headache, pain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Pruritus, skin rash</p>\n    <p style=\"text-indent:-4em;margin-left:4em;\">Gastrointestinal: Abdominal pain (Crohn disease; rheumatoid arthritis), dyspepsia, nausea</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Urinary tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Anemia (more common in children and adolescents with Crohn disease), leukopenia (more common in children and adolescents with Crohn disease), neutropenia (children and adolescents with Crohn disease)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Increased serum ALT</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Delayed hypersensitivity (plaque psoriasis), hypersensitivity reaction (more common in children and adolescents with Crohn disease), serum sickness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immunologic: Antibody development (double-stranded DNA), antibody development (more immunogenic when given as a single induction dose, episodic treatment, and monotherapy; Mayer 2006), increased ANA titer</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Abscess (Crohn disease patients with fistulizing disease), bacterial infection (children and adolescents with Crohn disease), candidiasis, infection (more common in adults and children with Crohn disease), serious infection (more common in children and adolescents), viral infection (children and adolescents with Crohn disease)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia, bone fracture (children and adolescents with Crohn disease)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Bronchitis, cough, pharyngitis, pneumonia, sinusitis, upper respiratory tract infection (rheumatoid arthritis; children and adolescents with ulcerative colitis)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever, infusion related reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Acute hepatic failure, agranulocytosis, anaphylaxis, autoimmune hepatitis, bradycardia, bronchospasm, cardiac arrhythmia, cellulitis, cerebrovascular accident, cholestasis, chronic inflammatory demyelinating polyneuropathy, coccidioidomycosis, constipation, cytomegalovirus disease, dehydration, demyelinating disease of the central nervous system, demyelinating disease (peripheral), dermal ulcer, diaphoresis, dizziness, edema, erythema multiforme, erythematous rash, exacerbation of psoriasis, Guillain-Barre syndrome, hemolytic anemia, hepatic failure, hepatic injury, hepatitis, hepatotoxicity (idiosyncratic) (Chalasani 2014), hepatosplenic T-cell lymphomas (mainly young adult or adolescent males), herpes zoster, histoplasmosis, Hodgkin lymphoma, hypotension, immune thrombocytopenia, increased serum AST, interstitial pulmonary disease, intestinal obstruction, ischemic heart disease, jaundice, laryngeal edema, leukemia, liver enzyme disorder (transient), lower respiratory tract infection, lupus-like syndrome, lymphadenopathy, malignant lymphoma, malignant melanoma, malignant neoplasm, malignant neoplasm of breast, malignant neoplasm of cervix, malignant neoplasm of colon or rectum, Merkel cell carcinoma, multiple sclerosis, myocardial infarction, neuropathy (includes multifocal motor), nocardiosis, non-Hodgkin lymphoma, opportunistic infection, optic neuritis, pancytopenia, pericardial effusion, pharyngeal edema, pleurisy, pneumocystosis, psoriasis (including new onset, palmoplantar, pustular), pulmonary edema, pulmonary fibrosis, reactivated tuberculosis, reactivation of HBV, sarcoidosis, seizure, sepsis, Stevens-Johnson syndrome, thrombocytopenia, thrombophlebitis, thrombotic thrombocytopenic purpura, toxic epidermal necrolysis, transverse myelitis, tuberculosis, urticaria, vasculitis (systemic and cutaneous), temporary vision loss</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182743\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to infliximab, murine proteins, or any component of the formulation; doses &gt;5 mg/kg in patients with moderate or severe heart failure (NYHA Class III/IV)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Severe infections (eg, sepsis, abscesses, tuberculosis, and opportunistic infections); use in patients with moderate or severe heart failure (NYHA Class III/IV)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182727\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Autoimmune disorder: Positive antinuclear antibody titers have been detected in patients (with negative baselines). Rare cases of autoimmune disorder, including lupus-like syndrome, have been reported; monitor and discontinue if symptoms develop.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular/cerebrovascular reactions during and following infusion: Cerebrovascular accidents, MI (some fatal), hypotension, hypertension, and arrhythmias have been reported within 24 hours of infusion. Transient vision loss has also been reported during or within 2 hours of infusion. Discontinue therapy if serious reaction occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hematologic disorders: Hematologic toxicities (eg, leukopenia, neutropenia, thrombocytopenia, pancytopenia) have been reported (may be fatal). Patients must be advised to seek medical attention if they develop signs and symptoms suggestive of blood dyscrasias (eg, persistent fevers); discontinue if significant hematologic abnormalities are confirmed. Use with caution in patients with history of hematologic abnormalities.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic reactions: Severe hepatic reactions (including hepatitis, jaundice, acute hepatic failure, and cholestasis) have been reported during treatment; reactions occurred between 2 weeks to &gt;1 year after initiation of therapy and some cases were fatal or necessitated liver transplantation; discontinue with jaundice and/or marked increase in liver enzymes (&ge;5 times ULN).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatitis B: Reactivation of hepatitis B virus (HBV) has occurred in chronic carriers of the virus, usually in patients receiving concomitant immunosuppressants (may be fatal); evaluate for HBV prior to initiation in all patients. Monitor during and for several months following discontinuation of treatment in HBV carriers; interrupt therapy if reactivation occurs and treat appropriately with antiviral therapy; if resumption of therapy is deemed necessary, exercise caution and monitor patient closely.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity or infusion reactions: Acute infusion reactions may occur. Hypersensitivity reactions, including anaphylaxis, may occur within 2 hours of infusion. Medication and equipment for management of hypersensitivity reaction should be available for immediate use. Interruptions and/or reinstitution at a slower rate may be required (consult protocols). Pretreatment may be considered, and may be warranted in all patients with prior infusion reactions. Serum sickness-like reactions have occurred; may be associated with a decreased response to treatment. The development of antibodies to infliximab may increase the risk of hypersensitivity and/or infusion reactions; concomitant use of immunosuppressants may lessen the development of anti-infliximab antibodies. The risk of infusion reactions may be increased with re-treatment after an interruption or discontinuation of prior maintenance therapy. Re-treatment in psoriasis patients should be resumed as a scheduled maintenance regimen without any induction doses; use of an induction regimen should be used cautiously for re-treatment of all other patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infections: <b>[US Boxed Warning]: Patients receiving infliximab are at increased risk for serious infections which may result in hospitalization and/or fatality; infections usually developed in patients receiving concomitant immunosuppressive agents (eg, methotrexate or corticosteroids) and may present as disseminated (rather than local) disease. Active tuberculosis (or reactivation of latent tuberculosis), invasive fungal (including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, and pneumocystosis) and bacterial, viral or other opportunistic infections (including legionellosis and listeriosis) have been reported. Monitor closely for signs/symptoms of infection. Discontinue for serious infection or sepsis. Consider risks versus benefits prior to use in patients with a history of chronic or recurrent infection. Consider empiric antifungal therapy in patients who are at risk for invasive fungal infection and develop severe systemic illness.</b> Caution should be exercised when considering use in the elderly or in patients with conditions that predispose them to infections (eg, diabetes) or residence/travel from areas of endemic mycoses (blastomycosis, coccidioidomycosis, histoplasmosis), or with latent or localized infections. Do not initiate infliximab therapy in patients with an active infection, including clinically important localized infection. Patients who develop a new infection while undergoing treatment should be monitored closely.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Malignancy: <b>[US Boxed Warning]: Lymphoma and other malignancies (may be fatal) have been reported in children and adolescent patients receiving TNF-blocking agents including infliximab.</b> Half the cases are lymphomas (Hodgkin's and non-Hodgkin's) and the other cases are varied but include malignancies not typically observed in this population. <b>[US Boxed Warning]: Postmarketing cases of hepatosplenic T-cell lymphoma have been reported in patients treated with infliximab. Almost all patients had received concurrent or prior treatment with azathioprine or mercaptopurine at or prior to diagnosis and the majority of reported cases occurred in adolescent and young adult males with Crohn disease or ulcerative colitis.</b> Malignancies occurred after a median of 30 months (range: 1 to 84 months) after the first dose of TNF blocker therapy; most patients were receiving concomitant immunosuppressants. The impact of infliximab on the development and course of malignancies is not fully defined. As compared to the general population, an increased risk of lymphoma has been noted in clinical trials; however, rheumatoid arthritis alone has been previously associated with an increased rate of lymphoma. Use caution in patients with a history of COPD, higher rates of malignancy were reported in COPD patients treated with infliximab. Psoriasis patients with a history of phototherapy had a higher incidence of nonmelanoma skin cancers. Melanoma and Merkel cell carcinoma have been reported in patients receiving TNF-blocking agents including infliximab. Perform periodic skin examinations in all patients during therapy, particularly those at increased risk for skin cancer. Women with rheumatoid arthritis had a higher incidence of invasive cervical cancer; periodic screening should be continued in women treated with infliximab.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tuberculosis: <b>[US Boxed Warning]: Infliximab treatment has been associated with active tuberculosis (may be disseminated or extrapulmonary) or reactivation of latent infections. Evaluate patients for tuberculosis risk factors and latent tuberculosis infection (with a tuberculin skin test) prior to and during therapy. Treatment of latent tuberculosis should be initiated before use. Patients with initial negative tuberculin skin tests should receive continued monitoring for tuberculosis throughout treatment.</b> Most cases of reactivation have been reported within the first couple months of treatment. Caution should be exercised when considering the use in patients who have been exposed to tuberculosis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Demyelinating CNS disease: Use with caution in patients with preexisting or recent onset CNS demyelinating disorders; rare cases of optic neuritis and demyelinating disease (including multiple sclerosis, systemic vasculitis, and Guillain-Barr&eacute; syndrome) have been reported; consider discontinuation of therapy if patient develops significant CNS reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Heart failure (HF): Use with caution in patients with mild HF (NYHA Class I, II) or decreased left ventricular function; worsening and new-onset HF has been reported; doses &gt;5 mg/kg should not be administered in patients with moderate to severe HF (NYHA Class III/IV); discontinue therapy with onset of new or worsening symptoms. In a scientific statement from the American Heart Association, TNF blockers have been determined to be agents that may either cause direct myocardial toxicity or exacerbate underlying myocardial dysfunction (magnitude: major) (AHA [Page 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizure disorders: Use with caution in patients with a history of seizures; discontinue if significant CNS adverse reactions develop.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Malignancies have been reported among children and adolescents receiving TNF-blocking agents. Efficacy was not established in a study to evaluate infliximab use in juvenile idiopathic arthritis (JIA).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immunizations: Patients should be brought up to date with all immunizations before initiating therapy. Live vaccines should not be given concurrently; there is no data available concerning secondary transmission of live vaccines in patients receiving therapy. A fatal outcome has been reported in an infant who received a live vaccine (BCG) after in utero exposure to infliximab; infliximab crosses the placenta and has been detected in infants&rsquo; serum for up to 6 months. It is recommended to wait &ge;6 months following birth before administering any live vaccine to infants exposed to infliximab in utero.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26023245\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">In an analysis of children and adolescents who had received TNF-blockers (etanercept and infliximab), the FDA identified 48 cases of malignancy. Of the 48 cases, ~50% were lymphomas (eg, Hodgkin and non-Hodgkin lymphoma). Other malignancies, such as leukemia, melanoma, Merkel cell carcinoma, and solid organ tumors, were reported; malignancies rarely seen in children (eg, leiomyosarcoma, hepatic malignancies, and renal cell carcinoma) were also observed. Of note, most of these cases (88%) were receiving other immunosuppressive medications (eg, azathioprine and methotrexate). As compared to the general population, an increased risk of lymphoma has been noted in clinical trials; however, rheumatoid arthritis has been previously associated with an increased rate of lymphoma. The role of TNF-blockers in the development of malignancies in children cannot be excluded. The FDA also reviewed 147 postmarketing reports of leukemia (including acute myeloid leukemia, chronic lymphocytic leukemia, and chronic myeloid leukemia) in patients (children and adults) using TNF blockers. Average onset time to development of leukemia was within the first 1 to 2 years of TNF-blocker initiation. Although most patients were receiving other immunosuppressive agents, the role of TNF blockers in the development of leukemia could not be excluded. The FDA concluded that there is a possible association with the development of leukemia and the use of TNF-blockers.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Reactivation of TB has been reported in pediatric patients receiving biologic response modifiers (infliximab and etanercept); prior to therapy, patients with no TB risk factors should be screened for latent TB infection (LTBI) with an age appropriate test (ie, &lt;5 years of age: tuberculin skin test, and &ge;5 years of age: IGRA [interferon gamma release assay]); if any TB risk factors are present or symptoms, both LTBI screening tests should be performed (AAP [Davies 2016])</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The risk of infusion-related reactions may be increased with retreatment after an interruption or discontinuation of prior maintenance dose. A retrospective study of 57 children receiving 361 infliximab infusions reported that the rate of infusion-related reactions in children was similar to that in adults (9.7% incidence reported). Female gender, immunosuppressive use for &lt;4 months, and prior infusion reactions were risk factors for subsequent infusion reactions in children (Crandall 2003).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299517\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182732\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13381&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Abatacept: Anti-TNF Agents may enhance the adverse/toxic effect of Abatacept. An increased risk of serious infection during concomitant use has been reported. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adalimumab: May enhance the immunosuppressive effect of InFLIXimab.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anakinra: Anti-TNF Agents may enhance the adverse/toxic effect of Anakinra. An increased risk of serious infection during concomitant use has been reported. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AzaTHIOprine: InFLIXimab may enhance the adverse/toxic effect of AzaTHIOprine. Specifically, the risk for T-cell non-Hodgkin's lymphoma (including hepatosplenic T-cell lymphoma) may be increased. InFLIXimab may increase serum concentrations of the active metabolite(s) of AzaTHIOprine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Belimumab: Monoclonal Antibodies may enhance the adverse/toxic effect of Belimumab. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Canakinumab: Anti-TNF Agents may enhance the adverse/toxic effect of Canakinumab. Specifically, the risk for serious infections and/or neutropenia may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Certolizumab Pegol: Anti-TNF Agents may enhance the immunosuppressive effect of Certolizumab Pegol. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Etanercept: May enhance the immunosuppressive effect of InFLIXimab.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Golimumab: May enhance the immunosuppressive effect of InFLIXimab.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rilonacept: Anti-TNF Agents may enhance the adverse/toxic effect of Rilonacept. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiopurine Analogs: Anti-TNF Agents may enhance the adverse/toxic effect of Thiopurine Analogs. Specifically, the risk for T-cell non-Hodgkin's lymphoma (including hepatosplenic T-cell lymphoma) may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May enhance the immunosuppressive effect of Anti-TNF Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Anti-TNF Agents may enhance the adverse/toxic effect of Tofacitinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ustekinumab: May enhance the immunosuppressive effect of InFLIXimab.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vedolizumab: Anti-TNF Agents may enhance the adverse/toxic effect of Vedolizumab. <i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182734\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182745\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Animal reproduction studies have not been conducted. Infliximab crosses the placenta and can be detected in the serum of infants for up to 6 months following in utero exposure. Agranulocytosis has been reported in infants exposed to infliximab in utero. A fatal outcome has been reported in an infant who received a live vaccine (BCG) after in utero exposure to infliximab; it is recommended to wait &ge;6 months following birth before administering any live vaccine to infants exposed to infliximab in utero. If a biologic agent such as infliximab is needed to treat inflammatory bowel disease during pregnancy, it is recommended to hold therapy after 30 weeks gestation (Habal 2012).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Health care providers are also encouraged to enroll women exposed to infliximab during pregnancy in the MotherToBaby Autoimmune Diseases Study by contacting the Organization of Teratology Information Specialists (OTIS) (877-311-8972).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047890\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor improvement of symptoms and physical function assessments. During infusion, if reaction is noted, monitor vital signs every 2 to 10 minutes, depending on reaction severity, until normal. Latent TB screening prior to initiating and during therapy; signs/symptoms of infection (prior to, during, and following therapy); CBC with differential; signs/symptoms/worsening of heart failure; HBV screening prior to initiating (all patients), HBV carriers (during and for several months following therapy); signs and symptoms of hypersensitivity reaction; symptoms of lupus-like syndrome; LFTs (discontinue if &gt;5 times ULN); signs and symptoms of malignancy (eg, splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Psoriasis patients with history of phototherapy should be monitored for nonmelanoma skin cancer.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182726\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Infliximab is a chimeric monoclonal antibody that binds to human tumor necrosis factor alpha (TNF&alpha;), thereby interfering with endogenous TNF&alpha; activity. Elevated TNF&alpha; levels have been found in involved tissues/fluids of patients with rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, Crohn disease and ulcerative colitis. Biological activities of TNF&alpha; include the induction of proinflammatory cytokines (interleukins), enhancement of leukocyte migration, activation of neutrophils and eosinophils, and the induction of acute phase reactants and tissue degrading enzymes. Animal models have shown TNF&alpha; expression causes polyarthritis, and infliximab can prevent disease as well as allow diseased joints to heal.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182742\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Note:</b> Pharmacokinetic data in pediatric patients (6 to 17 years) reported to be similar to adult values.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Crohn disease: 1 to 2 weeks; Rheumatoid arthritis: 3 to 7 days </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration of action: Crohn disease: 8 to 48 weeks; Rheumatoid arthritis: 6 to 12 weeks </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Within the vascular compartment;  V<sub>d</sub>: 3 to 6 L (Klotz 2007) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 7 to 12 days (Klotz 2007) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4370699\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Inflectra Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (1): $1,135.54</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Remicade Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (1): $1,401.38</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Renflexis Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (1): $904.07</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182747\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Flixabi (IE);</li>\n      <li>Inflectra (CY, CZ, DE, DK, EE, ES, FI, FR, GB, HR, IE, IS, LT, LU, LV, MT, NL, NO, PT, RO, SE, SK, TR);</li>\n      <li>Reemsima (EE);</li>\n      <li>Remicade (AE, AR, AT, AU, BB, BE, BG, BH, BR, CH, CL, CN, CO, CR, CY, CZ, DE, DK, DO, EE, ES, FI, FR, GB, GR, GT, HK, HN, HR, HU, ID, IE, IL, IN, IS, IT, JO, JP, KR, KW, LK, LT, LU, LV, MT, MX, MY, NI, NL, NO, NZ, PA, PE, PH, PL, PT, QA, RO, RU, SA, SE, SG, SI, SK, SV, TH, TR, UY, VE, VN);</li>\n      <li>Remmicade (LB);</li>\n      <li>Remsima (CY, CZ, DE, DK, ES, FI, FR, GB, HR, IE, IS, KR, LK, LT, LU, LV, MT, MY, NL, NO, PL, PT, RO, SE, SG, SK, TH, TR);</li>\n      <li>Remykeyd (UA);</li>\n      <li>Revellex (ZA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/infliximab-including-biosimilars-of-infliximab-pediatric-drug-information/abstract-text/3960626/pubmed\" target=\"_blank\" id=\"3960626\">3960626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Becker M, Ros&eacute; CD, and McIlvain-Simpson G, &quot;Niacin-Like Reaction to Infliximab Infusion in Systemic Juvenile Rheumatoid Arthritis,&quot; <i>J Rheumatol</i>, 2004, 31(12):2529-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/infliximab-including-biosimilars-of-infliximab-pediatric-drug-information/abstract-text/15570667/pubmed\" target=\"_blank\" id=\"15570667\">15570667</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ben-Horin S, Yavzori M, Kopylov U, et al. Detection of infliximab in breast milk of nursing mothers with inflammatory bowel disease. <i>J Crohns Colitis</i>. 2011;5(6):555-558.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/infliximab-including-biosimilars-of-infliximab-pediatric-drug-information/abstract-text/22115374/pubmed\" target=\"_blank\" id=\"22115374\">22115374</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Burns JC, Mason WH, Hauger SB, et al. Infliximab treatment for refractory Kawasaki syndrome. <i>J Pediatr</i>. 2005;146(5):662-667.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/infliximab-including-biosimilars-of-infliximab-pediatric-drug-information/abstract-text/15870671/pubmed\" target=\"_blank\" id=\"15870671\">15870671</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Burns JC, Best BM, Mejias A, et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. <i>J Pediatr</i>. 2008;153(6):833-838.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/infliximab-including-biosimilars-of-infliximab-pediatric-drug-information/abstract-text/18672254/pubmed\" target=\"_blank\" id=\"18672254\">18672254</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product.<i> MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/infliximab-including-biosimilars-of-infliximab-pediatric-drug-information/abstract-text/6423951/pubmed\" target=\"_blank\" id=\"6423951\">6423951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Crandall WV and Mackner LM, &ldquo;Infusion Reactions to Infliximab in Children and Adolescents: Frequency, Outcome and a Predictive Model,&rdquo; <i>Aliment Pharmacol Ther</i>, 2003, 17(1):75-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/infliximab-including-biosimilars-of-infliximab-pediatric-drug-information/abstract-text/12492735/pubmed\" target=\"_blank\" id=\"12492735\">12492735</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Davies HD, Committee on Infectious Disease. Infectious complications with the use of biologic response modifiers in infants and children. <i>Pediatrics</i>. 2016;138(2):e20161209.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/infliximab-including-biosimilars-of-infliximab-pediatric-drug-information/abstract-text/27432853/pubmed\" target=\"_blank\" id=\"27432853\">27432853</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Habal FM, Huang VW. Review article: a decision-making algorithm for the management of pregnancy in the inflammatory bowel disease patient. <i>Aliment Pharmacol Ther</i>. 2012;35(5):501-515.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/infliximab-including-biosimilars-of-infliximab-pediatric-drug-information/abstract-text/22221203/pubmed\" target=\"_blank\" id=\"22221203\">22221203</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ikeda R, Vermeulen LC, Lau E, et al. Stability of infliximab in polyvinyl chloride bags. <i>Am J Health Syst Pharm</i>. 2012;69(17):1509-1512.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Inflectra (infliximab) [prescribing information]. New York, New York: Pfizer Labs; June 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/infliximab-including-biosimilars-of-infliximab-pediatric-drug-information/abstract-text/12534540/pubmed\" target=\"_blank\" id=\"12534540\">12534540</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Klotz U, Teml A, and Schwab M, &quot;Clinical Pharmacokinetics and Use of Infliximab,&quot; <i>Clin Pharmacokinet</i>, 2007, 46(8):645-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/infliximab-including-biosimilars-of-infliximab-pediatric-drug-information/abstract-text/17655372/pubmed\" target=\"_blank\" id=\"17655372\">17655372</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lahdenne P, Wikstr&ouml;m AM, Aalto K, et al, &quot;Prevention of Acute Adverse Events Related to Infliximab Infusions in Pediatric Patients,&quot; <i>Arthritis Care Res (Hoboken)</i>, 2010, 62(6):785-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/infliximab-including-biosimilars-of-infliximab-pediatric-drug-information/abstract-text/20535789/pubmed\" target=\"_blank\" id=\"20535789\">20535789</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/infliximab-including-biosimilars-of-infliximab-pediatric-drug-information/abstract-text/10985636/pubmed\" target=\"_blank\" id=\"10985636\">10985636</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mayer L and Young Y, &quot;Infusion Reactions and Their Management,&quot; <i>Gastroenterol Clin North Am</i>, 2006, 35(4):857-66.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/infliximab-including-biosimilars-of-infliximab-pediatric-drug-information/abstract-text/17129817/pubmed\" target=\"_blank\" id=\"17129817\">17129817</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long-term management of Kawasaki Disease: a scientific statement for health professionals from the American Heart Association. <i>Circulation</i>. 2017;135(17):e927-e999.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/infliximab-including-biosimilars-of-infliximab-pediatric-drug-information/abstract-text/28356445/pubmed\" target=\"_blank\" id=\"28356445\">28356445</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Page RL 2nd, O'Bryant CL, Cheng D, et al. Drugs that may cause or exacerbate heart failure: a scientific statement from the American Heart Association. <i>Circulation</i>. 2016;134(6):e32-69.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/infliximab-including-biosimilars-of-infliximab-pediatric-drug-information/abstract-text/27400984/pubmed\" target=\"_blank\" id=\"27400984\">27400984</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Remicade (infliximab) [prescribing information]. Horsham, PA: Janssen Biotech, Inc.; October 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Renflexis (infliximab) [prescribing information]. Whitehouse Station, NJ: Merck Sharp &amp; Dohme Corp; April 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rufo PA, Denson LA, Sylvester FA, et al, &quot;Health Supervision in the Management of Children and Adolescents With IBD: NASPGHAN Recommendations,&quot; <i>J Pediatr Gastroenterol Nutr</i>, 2012, 55(1):93-108.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/infliximab-including-biosimilars-of-infliximab-pediatric-drug-information/abstract-text/22516861/pubmed\" target=\"_blank\" id=\"22516861\">22516861</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ruperto N, Lovell DJ, Cuttica R, et al, &quot;A Randomized, Placebo-Controlled Trial of Infliximab Plus Methotrexate for the Treatment of Polyarticular-Course Juvenile Rheumatoid Arthritis,&quot; <i>Arthritis Rheum</i>, 2007, 56(9):3096-106.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/infliximab-including-biosimilars-of-infliximab-pediatric-drug-information/abstract-text/17763439/pubmed\" target=\"_blank\" id=\"17763439\">17763439</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ruperto N, Lovell DJ, Cuttica R, et al, &quot;Long-Term Efficacy and Safety of Infliximab Plus Methotrexate for the Treatment of Polyarticular Course Juvenile Rheumatoid Arthritis: Findings From an Open-Label Treatment Extension,&quot; <i>Ann Rheum Dis</i>, 2009 [Epub ahead of print].<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/infliximab-including-biosimilars-of-infliximab-pediatric-drug-information/abstract-text/19406734 /pubmed\" target=\"_blank\" id=\"19406734 \">19406734 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8960):1312-1313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/infliximab-including-biosimilars-of-infliximab-pediatric-drug-information/abstract-text/7746084/pubmed\" target=\"_blank\" id=\"7746084\">7746084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Son MB, Gauvreau K, Burns JC, et al. Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: a retrospective study. <i>J Pediatr</i>. 2011;158(4):644-649.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/infliximab-including-biosimilars-of-infliximab-pediatric-drug-information/abstract-text/21129756/pubmed\" target=\"_blank\" id=\"21129756\">21129756</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stephens MC, Shepanski MA, Mamula P, et al, &ldquo;Safety and Steroid-Sparing Experience Using Infliximab for Crohn's Disease at a Pediatric Inflammatory Bowel Disease Center,&rdquo; <i>Am J Gastroenterol</i>, 2003, 98(1):104-11.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/infliximab-including-biosimilars-of-infliximab-pediatric-drug-information/abstract-text/12526944/pubmed\" target=\"_blank\" id=\"12526944\">12526944</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Thayu M, Markowitz JE, Mamula P, et al, &quot;Hepatosplenic T-Cell Lymphoma in an Adolescent Patient After Immunomodulator and Biologic Therapy for Crohn Disease,&quot; <i>J Pediatr Gastroenterol Nutr</i>, 2005, 40(2):220-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/infliximab-including-biosimilars-of-infliximab-pediatric-drug-information/abstract-text/15699701/pubmed\" target=\"_blank\" id=\"15699701\">15699701</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tremoulet AH, Jain S, Jaggi P, et al. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial. <i>Lancet.</i> 2014;383(9930):1731-1738.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/infliximab-including-biosimilars-of-infliximab-pediatric-drug-information/abstract-text/24572997/pubmed\" target=\"_blank\" id=\"24572997\">24572997</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Visvanathan S, Wagner C, Marini JC, et al, &quot;The Effect of Infliximab Plus Methotrexate on the Modulation of Inflammatory Disease Markers in Juvenile Idiopathic Arthritis: Analyses From a Randomized, Placebo-Controlled Trial,&quot; <i>Pediatr Rheumatol Online J</i>, 2010, 8:24.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/infliximab-including-biosimilars-of-infliximab-pediatric-drug-information/abstract-text/20822542/pubmed\" target=\"_blank\" id=\"20822542\">20822542</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weiss JE, Eberhard BA, Chowdhury D, Gottlieb BS. Infliximab as a novel therapy for refractory Kawasaki disease. <i>J Rheumatol</i>. 2004;31(4):808-810.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/infliximab-including-biosimilars-of-infliximab-pediatric-drug-information/abstract-text/15088313/pubmed\" target=\"_blank\" id=\"15088313\">15088313</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wilkinson N, Jackson G, and Gardner-Medwin J, &ldquo;Biologic Therapies for Juvenile Arthritis,&rdquo; <i>Arch Dis Child</i>, 2003, 88(3):186-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/infliximab-including-biosimilars-of-infliximab-pediatric-drug-information/abstract-text/12598373 /pubmed\" target=\"_blank\" id=\"12598373 \">12598373 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Youn Y, Kim J, Hong YM, Sohn S. Infliximab as the first retreatment in patients with Kawasaki Disease resistant to initial intravenous immunoglobulin. <i>Pediatr Infect Dis J</i>. 2016;35(4):457-459.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/infliximab-including-biosimilars-of-infliximab-pediatric-drug-information/abstract-text/26673981/pubmed\" target=\"_blank\" id=\"26673981\">26673981</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13381 Version 147.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708921\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F182756\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F182757\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1047891\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1047884\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F182738\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F182723\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F27749143\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F50858894\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F7874621\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1047894\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F182751\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1047893\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F182793\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F182789\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F182743\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F182727\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F26023245\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299517\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F182732\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F182734\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F182745\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1047890\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F182726\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F182742\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F4370699\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F182747\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13381|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=infliximab-including-biosimilars-of-infliximab-drug-information\" class=\"drug drug_general\">Infliximab (including biosimilars of infliximab): Drug information</a></li><li><a href=\"topic.htm?path=infliximab-including-biosimilars-of-infliximab-patient-drug-information\" class=\"drug drug_patient\">Infliximab (including biosimilars of infliximab): Patient drug information</a></li></ul></div></div>","javascript":null}